Please assess the completion status of the following clinical trial:

Trial Title: Comparative Prevalence of Psychiatric Manifestations in Purely Obstetrical Antiphospholipid Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The patient must have given his/her informed and signed consent~* The patient must be insured or beneficiary of a health insurance plan~* Not postmenopausal~* Able to understand the nature, purpose and methodology of the study and agreed to cooperate in clinical and biological assessments~* Available for 12 weeks of follow-up~* Isolated obstetric morbidity, defined by at least one of the following criteria:~* at least three consecutive episodes of unexplained, early, embryonic miscarriage, which occurred before the 10th week of pregnancy, with normal maternal anatomic and hormonal assessment, normal karyotypes for both biological parents;~* at least one unexplained fetal death, defined as occurring after the 10th week of pregnancy, involving a morphologically normal fetus as documented by ultrasound examination or direct examination of the conceptus;~* at least one premature birth of a morphologically normal fetus before the 34th week of pregnancy, because of: (1) pre-eclampsia, severe or not, according to the American College of Obstetrics and Gynecology, ACOG, 2002; (2)documented placental insufficiency, defined by the following parameters: (2a) abnormal or non-reassuring fetal monitoring exam, in general a non-reactive absence-of-fetal-stress test (fetal monitoring), suggesting fetal hypoxemia; (2b) a Doppler examination of uterine arteries suggesting fetal hypoxemia, ie the absence of end-diastolic flow in the umbilical arteries; (2c) oligohydramnios, that is to say, an amniotic flow index \<5 cm; (2d) indexed birth weight for gestational age and sex below the 10th percentile.~* Patient willing to accept psychological and medical care over the long term~Exclusion Criteria:~* The patient is participating in another study~* The patient is in an exclusion period determined by a previous study~* The patient is under judicial protection, under tutorship or curatorship~* The patient refuses to sign the consent~* It is impossible to correctly inform the patient~* The patient is pregnant, parturient or breastfeeding~* Systemic vascular morbidity, defined by the following criteria: (1) Any personal history of venous thromboembolism, defined by the occurrence of deep phlebitis and / or a pulmonary embolism, diagnosed by means of objective exploration ; (2)Any personal history of superficial venous thrombosis; (3) Any personal history of clinical, symptomatic relapses of arterial insufficiency - the latter may be cerebro vascular in nature (transient ischemic attack, stroke, etc..), coronary in nature (angina, myocardial infarction, etc..) or otherwise (claudication mesenteric, etc.), and objectively diagnosed.~* Systemic inflammatory disease: any history of systemic disease, lupus erythematosus or other connective, rheumatoid arthritis~* Any history of neoplastic disease~* Chronic antithrombotic treatment taken before the occurrence of obstetrical complications~* Any chronic immunosuppressive therapy or immunomodulatory therapy (eg corticosteroids, hydroxochloroquine or intravenous immunoglobulins)~* Fetal loss can be explained by infectious, metabolic (including rates of fasting blood glucose\> 7 mmol / L), anatomical or hormonal factors~* History of infection with hepatitis B, hepatitis C or HIV~* Taking antipsychotic treatment potentially implicated in biological autoimmune abnormalities

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Suspected Obstetrical APS; confirmed APS (Type: OTHER): The patients included in this study are women actively addressed to the participating departments because of clinical symptoms corresponding to suspected obstetrical anti-phospholipid syndrome.~Bloodwork later confirms that these patients have APS.~All patients included in this study will have the following interventions:~* antiphospholipid antibody tests~* thrombophilia bloodwork~* psychiatric evaluation
- Sus. Obst. APS, confirmed thrombophilia (Type: OTHER): The patients included in this study are women actively addressed to the participating departments because of clinical symptoms corresponding to suspected obstetrical anti-phospholipid syndrome.~Bloodwork later confirms that these patients are thrombophilic.~All patients included in this study will have the following interventions:~* antiphospholipid antibody tests~* thrombophilia bloodwork~* psychiatric evaluation
- Suspected Obstectrical APS; unconfirmed (Type: OTHER): The patients included in this study are women actively addressed to the participating departments because of clinical symptoms corresponding to suspected obstetrical anti-phospholipid syndrome.~Bloodwork cannot confirm APS, nor thrombophilia.~All patients included in this study will have the following interventions:~* antiphospholipid antibody tests~* thrombophilia bloodwork~* psychiatric evaluation

Based on this trial design, predict the completion outcome and termination type (if applicable).